H2 tag- SEO Purpose
5-ARI: 5-alpha-reductase inhibitor; BPH: Benign prostatic hyperplasia; IFIS: Intraoperative floppy iris syndrome; LUTS: Lower urinary tract symptoms.
Prevalence and impact of BPH
One of the most prevalent genitourinary conditions observed among men aged over 50 years is BPH.1 Nearly 8 out of 10 men experience it at some point in their lifetime.2 Beyond its rising prevalence, BPH also brings significant challenges, including increased morbidity, complications, and healthcare costs. Additionally, it significantly impacts the patient’s quality of life.3
Management approaches for BPH
Over the past 20 years, treatments for BPH have transitioned from surgical options to drug therapy.1 Current recommendations for the pharmacological management of BPH include alpha-blockers, 5-ARIs, and phosphodiesterase-5 inhibitors, either alone or in combination.1 While drug treatments are generally viewed as lower risk than surgery, it is crucial for both clinicians and patients to recognize that they still carry some risks.2 Adverse sexual side effects may arise from the drug class as a whole or specific medications within these classes.1,2
Therefore, when treating BPH, it is crucial to consider male sexual function, the patient's age and comorbidities, the severity of symptoms at presentation, and the overall effects of each drug class to ensure optimal care.1,3
Alfoo- Relief from LUTS-BPH
ALFOO, containing Alfuzosin molecule, is Anti-BPH which helps in treatment of LUTS due to BPH in Young Sexually Active Male in 40-60 year old age group
